UAE investors are focusing on the GLP-1 market as the broader healthcare sector weakens in early 2026. The release frames GLP-1 obesity drugs as a growth area with global sales projected to reach USD 39.4 billion in 2026 and potentially surpass USD 100 billion by decade’s end, underscoring why capital is watching the space closely. It notes that investors are prioritising companies with durable pipelines and clear catalysts, while new entrants and digital-health strategies are reshaping how treatments reach patients. Market commentary from Josh Gilbert of eToro is cited, describing healthcare as a stock-picker’s market as investors weigh growth against regulatory and competitive headwinds.

Key points

GLP-1 market forecast: global GLP-1 sales projected at USD 39.4 billion in 2026, with potential to exceed USD 100 billion by decade end.
Public-market signals: Moderna +65%, J&J +16.8%, Merck +14.4%, Pfizer +12.4%, and Gilead +~16% YTD; emphasizes selective stock-picking in healthcare.
Near-term headwinds: US GLP-1 price reductions expected to cut obesity drug revenues by USD 2–3 billion this year.
New entrants and digital health: Hims & Hers Health partners with Novo Nordisk for direct-to-consumer GLP-1 access (2.5 million subscribers); WHOOP funding at USD 10.1B valuation with potential IPO.

Why it matters

The note highlights how GLP-1 growth remains a central theme for healthcare investors even amid sector volatility. Forecasted scale, coupled with pipeline strength and digital-access strategies, suggests selective exposure may outperform, while pricing pressures and regulatory developments could constrain near-term gains. For readers and market participants, the briefing signals where attention may shift—toward durable pipelines, scalable access models, and the ability to navigate evolving regulatory and competitive landscapes.

What to watch

US GLP-1 price reductions (25–35%) and their potential impact on obesity-drug revenues (estimated at USD 2–3 billion this year).
Guidance and pipeline updates from Novo Nordisk and Eli Lilly, given recent share declines tied to weaker guidance and market concerns.
Digital-health entrants and access strategies, including Hims & Hers Health’s partnership with Novo Nordisk and WHOOP’s IPO considerations.

Disclosure: The content below is a press release provided by the company or its PR representative. It is published for informational purposes.

UAE Investors Eye $39.4B GLP-1 Market Despite Healthcare Sector Weakness

Abu Dhabi, UAE – April 07, 2026: The healthcare sector has faced a difficult start to 2026, declining 5.5% year-to-date and underperforming the broader S&P 500, which is down 3.3%. However, the divergence in performance across the sector highlights a growing gap between winners and losers, reinforcing the importance of selective stock picking.

Several major pharmaceutical companies have delivered strong returns, with Moderna up 65%, Johnson & Johnson rising 16.8%, Merck gaining 14.4%, Pfizer up 12.4%, and Gilead Sciences advancing nearly 16%. This reflects investor preference for companies with robust pipelines, resilient earnings, and clear strategic catalysts, while higher-growth, higher-valuation names have come under pressure.

“Healthcare is increasingly becoming a stock-picker’s market,” said Josh Gilbert, Market Analyst at eToro. “Investors are prioritising companies that can deliver consistent performance regardless of macro uncertainty, and that’s where established pharma players are standing out.”

The GLP-1 obesity drug market remains one of the most significant growth stories in the pharmaceutical landscape. Global sales are projected to reach USD 39.4 billion (AED 144.7 billion) in 2026 and could exceed USD 100 billion (AED 367.25 billion) by the end of the decade. However, recent developments have introduced near-term headwinds for key players.

Novo Nordisk shares have declined 24% year-to-date following weaker sales guidance and disappointing trial results for its next-generation obesity drug, CagriSema. Eli Lilly has also fallen 14%, driven by valuation concerns and questions around the total addressable market. Additionally, a recent agreement with the White House to reduce GLP-1 drug prices by 25–35% is expected to cut combined US obesity drug revenues by USD 2–3 billion (AED 7–11 billion) this year.

“While the long-term opportunity in GLP-1 remains substantial, the market is starting to price in competitive and regulatory pressures,” Gilbert added. “Much like the AI space, this is becoming a race to scale efficiently and maintain innovation leadership.”

New entrants are also shaping the landscape. Hims & Hers Health, despite shares falling 37% amid regulatory scrutiny, has attracted attention through its partnership with Novo Nordisk, enabling direct-to-consumer access to GLP-1 treatments via a digital platform. The company has already built a subscriber base of 2.5 million, reflecting growing demand for more accessible, tech-enabled healthcare solutions.

Beyond pharmaceuticals, momentum is building in healthcare technology and wearables. WHOOP recently secured USD 575 million (AED 2.1 billion) in funding at a USD 10.1 billion (AED 37 billion) valuation, with backing from major investors including Mubadala, Qatar Investment Authority, Abbott, and Mayo Clinic. The company has indicated that an IPO could be the next step.

“This signals a broader shift towards AI-driven, subscription-based health ecosystems,” said Gilbert. “Investors are increasingly recognising digital health and wearables as the next major frontier in consumer technology.”

Overall, the healthcare sector continues to offer a compelling investment case. Its defensive characteristics remain attractive in a volatile, headline-driven market, while long-term structural trends—from GLP-1 innovation to digital health adoption—continue to accelerate.

About eToro

Etoro

eToro is the trading and investing platform that empowers you to invest, share and learn. We were founded in 2007 with the vision of a world where everyone can trade and invest in a simple and transparent way. Today we have 40 million registered users from 75 countries. We believe there is power in shared knowledge and that we can become more successful by investing together. So we’ve created a collaborative investment community designed to provide you with the tools you need to grow your knowledge and wealth. On eToro, you can hold a range of traditional and innovative assets and choose how you invest: trade directly, invest in a portfolio, or copy other investors. You can visit our media centre here for our latest news.

Disclaimers:

Not investment advice. eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

eToro is a group of companies that are authorised and regulated in their respective jurisdictions. The regulatory authorities overseeing eToro include:

The Financial Conduct Authority (FCA) in the UK
The Cyprus Securities and Exchange Commission (CySEC) in Cyprus
The Australian Securities and Investments Commission (ASIC) in Australia
The Financial Services Authority (FSA) in the Seychelles
The Financial Services Regulatory Authority (FSRA) of the Abu Dhabi Global Market (ADGM) in the UAE
The Monetary Authority of Singapore (MAS) in Singapore

This communication is for information and education purposes only and should not be taken as investment advice, a personal recommendation, or an offer of, or solicitation to buy or sell, any financial instruments. This material has been prepared without taking into account any particular recipient’s investment objectives or financial situation, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication.

Regulation and License numbers

eToro (UK) Ltd, is authorised and regulated by the Financial Conduct Authority (“FCA”). Firm Reference Number: 583263. Registered in England under Company No. 07973792

Europe

eToro (Europe) Ltd, is authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC) under licence number 109/10. Registered in Cyprus under Company No. HE 200585.

Middle East

eToro (ME) Limited, is licensed and regulated by the Abu Dhabi Global Market (“ADGM”)’s Financial Services Regulatory Authority (“FSRA“) as an Authorised Person to conduct the Regulated Activities of (a) Dealing in Investments as Principal (Matched), (b) Arranging Deals in Investments, (c) Providing Custody, (d) Arranging Custody and (e) Managing Assets (under Financial Services Permission Number 220073) under the Financial Services and Market Regulations 2015 (“FSMR”). Registered Office and its principal place of business: Office 26 and 27, 25th floor, Al Sila Tower, ADGM Square, Al Maryah Island, Abu Dhabi, United Arab Emirates.

Australia

eToro AUS Capital Limited (AFSL number 491139) and eToro Asset Management Limited (AFSL 319738) (“collectively, eToro Australia”) is regulated by the Australian Securities & Investments Commission (“ASIC”) for the provision of financial services and products.

Singapore

eToro Singapore Pte. Ltd. is licensed under the Capital Markets Services Licence (“CMSL”) (Licence number: CMS101824) with the Monetary Authority of Singapore (“MAS”).